Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the weight loss drugs, according to a new report.

The Trump administration is reportedly considering a way to ease Medicare and Medicaid into covering GLP-1 drugs like Ozempic and Mounjaro for obesity starting as soon as next year. Why it matters: The Health and Human Services Department in April rejected a Biden administration proposal to allow Medicare and Medicaid to cover the injections for weight-loss.

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, while the Trump administration appears to be backing away from a campaig | The Trump administration has not adamantly pursued policies in support of in vitro fertilization coverage,